A detailed history of Ubs Group Ag transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 80,633 shares of FULC stock, worth $241,092. This represents 0.0% of its overall portfolio holdings.

Number of Shares
80,633
Previous 190,551 57.68%
Holding current value
$241,092
Previous $1.18 Million 75.7%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.18 - $9.74 $349,539 - $1.07 Million
-109,918 Reduced 57.68%
80,633 $287,000
Q2 2024

Aug 13, 2024

BUY
$5.98 - $9.31 $704,342 - $1.1 Million
117,783 Added 161.86%
190,551 $1.18 Million
Q1 2024

May 13, 2024

BUY
$6.7 - $12.0 $285,319 - $511,020
42,585 Added 141.09%
72,768 $686,000
Q4 2023

Feb 09, 2024

BUY
$3.18 - $6.86 $60,502 - $130,518
19,026 Added 170.53%
30,183 $203,000
Q3 2023

Nov 09, 2023

SELL
$3.25 - $6.08 $66,956 - $125,260
-20,602 Reduced 64.87%
11,157 $49,000
Q2 2023

Aug 11, 2023

BUY
$2.26 - $3.8 $70,817 - $119,073
31,335 Added 7390.33%
31,759 $104,000
Q1 2023

May 12, 2023

SELL
$2.83 - $13.99 $9,522 - $47,076
-3,365 Reduced 88.81%
424 $1,000
Q4 2022

Feb 08, 2023

BUY
$5.01 - $8.35 $18,982 - $31,638
3,789 New
3,789 $27,000
Q2 2022

Aug 10, 2022

SELL
$4.2 - $24.0 $6,169 - $35,256
-1,469 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$9.96 - $23.65 $6,414 - $15,230
644 Added 78.06%
1,469 $35,000
Q4 2021

Feb 14, 2022

SELL
$14.0 - $28.44 $6,720 - $13,651
-480 Reduced 36.78%
825 $15,000
Q3 2021

Nov 15, 2021

BUY
$7.28 - $30.97 $2,642 - $11,242
363 Added 38.54%
1,305 $37,000
Q2 2021

Aug 13, 2021

SELL
$8.09 - $12.0 $4,684 - $6,948
-579 Reduced 38.07%
942 $10,000
Q1 2021

May 12, 2021

BUY
$10.94 - $15.32 $13,029 - $18,246
1,191 Added 360.91%
1,521 $18,000
Q4 2020

Feb 11, 2021

SELL
$7.84 - $13.4 $22,704 - $38,806
-2,896 Reduced 89.77%
330 $4,000
Q3 2020

Nov 12, 2020

SELL
$7.22 - $20.7 $8,043 - $23,059
-1,114 Reduced 25.67%
3,226 $26,000
Q2 2020

Jul 31, 2020

SELL
$9.11 - $22.06 $34,372 - $83,232
-3,773 Reduced 46.51%
4,340 $79,000
Q1 2020

May 01, 2020

BUY
$9.49 - $21.26 $19,036 - $42,647
2,006 Added 32.85%
8,113 $97,000
Q4 2019

Feb 14, 2020

BUY
$4.46 - $18.14 $7,421 - $30,184
1,664 Added 37.45%
6,107 $101,000
Q3 2019

Nov 14, 2019

BUY
$6.64 - $14.89 $29,501 - $66,156
4,443 New
4,443 $29,000

Others Institutions Holding FULC

About Fulcrum Therapeutics, Inc.


  • Ticker FULC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,038,900
  • Market Cap $156M
  • Description
  • Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...
More about FULC
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.